None
Quote | AnaptysBio Inc. (NASDAQ:ANAB)
Last: | $25.47 |
---|---|
Change Percent: | -0.53% |
Open: | $24.88 |
Close: | $25.47 |
High: | $25.98 |
Low: | $24.83 |
Volume: | 271,693 |
Last Trade Date Time: | 07/08/2024 03:00:00 am |
News | AnaptysBio Inc. (NASDAQ:ANAB)
2024-07-08 08:55:24 ET Summary AnaptysBio, Inc. receives a "Hold" rating for its U.S.-listed shares. It shows a 16.42% increase in stock market value since the last "Buy" rating. AnaptysBio's immunotherapy portfolio includes promising projects such as Rosnilimab, ANB032, ANB033, I...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Message Board Posts | AnaptysBio Inc. (NASDAQ:ANAB)
Subject | By | Source | When |
---|---|---|---|
HighPeaks, The NY Times article was | gfp927z | investorshub | 06/10/2022 4:40:20 PM |
Thanks TP. Yeah this has the potential to | HighPeaks | investorshub | 06/10/2022 3:36:11 PM |
Tremendous find HighPeaks. .You have been early on | tedpeele | investorshub | 06/10/2022 5:30:31 AM |
According to this link ANAB gets 8-25% royalties | HighPeaks | investorshub | 06/08/2022 7:33:46 PM |
$ANAB / #Anaptysbio Spikes After Drug Designation | TFMG | investorshub | 07/09/2020 1:28:42 AM |
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least 24 weeks maintained clear to almost clear skin and none experienced a flare ...